Adebrelimab before surgery for esophageal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called adebrelimab given before surgery for esophageal cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that can be surgically removed.
- Your cancer is stage II or III based on scans and has not spread to nearby lymph nodes above the collarbone.
- You are between 18 and 75 years old and are in good overall health (able to do daily activities).
- You have not received any previous cancer treatment like chemotherapy, radiation, or surgery for this cancer.
- Your liver, kidney, and blood counts are within normal ranges, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy before surgery for esophageal squamous cell carcinoma (a type of throat cancer). The goal is to shrink the tumor and improve outcomes before the surgical removal of the cancer.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a drug called Adebrelimab (an immunotherapy) given before surgery to treat esophageal squamous cell cancer. It compares 2 cycles of treatment with 4 cycles to see which works better. The goal is to shrink the tumor and make surgery more effective.
This study tests a combination of two drugs (a type of immunotherapy called adebrelimab and an immune-boosting drug called thymalfasin) given with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve the chances of a successful surgery.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.